comparemela.com
Home
Live Updates
CSLs Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance : comparemela.com
CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance
/PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the U.S. Food and Drug Administration (FDA) has accepted the company's...
Related Keywords
Australia ,
Emmanuelle Lecomte Brisset ,
Kim Odonohue ,
Jimmy Baker ,
Valerie Bomberger ,
Global Head Of Regulatory Affairs ,
Drug Administration ,
Twitter ,
European Medicines Agency ,
European Union ,
Biologics License Application ,
Authorization Application ,
Senior Vice President ,
Global Head ,
Regulatory Affairs ,
Csl ,
comparemela.com © 2020. All Rights Reserved.